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Abstract 
Background: Artemisinin-based combination therapy (ACT) is recommended to improve malaria treatment efficacy 
and limit drug-resistant parasites selection in malaria endemic areas. 5 years after they were adopted, the efficacy and 
safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ), the first-line treatments for uncompli-
cated malaria were assessed in Burkina Faso.
Methods: In total, 440 children with uncomplicated Plasmodium falciparum malaria were randomized to receive 
either AL or ASAQ for 3 days and were followed up weekly for 42 days. Blood samples were collected to investigate 
the ex vivo susceptibility of P. falciparum isolates to lumefantrine, dihydroartemisinin (the active metabolite of arte-
misinin derivatives) and monodesethylamodiaquine (the active metabolite of amodiaquine). The modified isotopic 
micro test technique was used to determine the 50% inhibitory concentration (IC50) values. Primary endpoints were 
the risks of treatment failure at days 42.
Results: Out of the 440 patients enrolled, 420 (95.5%) completed the 42 days follow up. The results showed a 
significantly higher PCR unadjusted cure rate in ASAQ arm (71.0%) than that in the AL arm (49.8%) on day 42, and 
this trend was similar after correction by PCR, with ASAQ performing better (98.1%) than AL (91.1%). Overall adverse 
events incidence was low and not significantly different between the two treatment arms. Ex vivo results showed that 
6.4% P. falciparum isolates were resistant to monodesthylamodiaquine. The coupled in vivo/ex vivo analysis showed 
increased IC50 values for lumefantrine and monodesethylamodiaquine at day of recurrent parasitaemia compared to 
baseline values while for artesunate, IC50 values remained stable at baseline and after treatment failure (p > 0.05).
Conclusion: These findings provide substantial evidence that AL and ASAQ are highly efficacious for the treatment 
of uncomplicated malaria in children in Burkina Faso. However, the result of P. falciparum susceptibility to the partner 
drugs advocates the need to regularly replicate such surveillance studies. This would be particularly indicated when 
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Background
Although the global incidence of malaria has decreased 
with 41% and its related mortality with 62% between 
2000 and 2015, Plasmodium falciparum malaria remains 
a deadly endemic parasitic disease with over 219 million 
new cases and above 435,000 deaths reported in 2017 [1]. 
Approximately 92% of the falciparum malaria cases occur 
in sub-Saharan Africa and 70% of them are children 
under 5 years of age [1]. The World Health Organization 
(WHO) guidelines recommend a 3-day regimen of arte-
misinin-based combination therapy (ACT) for the treat-
ment of uncomplicated malaria, and ACT has become 
crucial in efforts to eliminate malaria [2]. The extensive 
deployment of ACT combined with vector control meas-
ures led to a substantial decrease in malaria transmis-
sion and its public health consequences [3]. However, 
these efforts could be jeopardized by the occurrence and 
spread of artemisinin resistance in P. falciparum malaria, 
as this was already reported in South-East Asia [4–8]. As 
of 2019, artemisinin resistance has been confirmed in six 
countries of the Greater Mekong Sub-region [9].
By analogy to the history of chloroquine resist-
ance and recent reports of declining ACT efficacy in 
Africa, it can be predicted that ACT resistance may 
spread from South-East Asia to India and progres-
sively to sub-Saharan Africa within few years [9, 10]. 
Indeed, declining parasitological response rates to 
treatment and sub-microscopic persistence of P. falci-
parum after treatment with ACT have been reported 
in Africa; possibly due to the emergence of parasites 
with reduced drug sensitivity [10–12]. Resistance to 
amodiaquine, the partner drug in the artesunate–amo-
diaquine (ASAQ) combination, mediated principally 
by mutations in 2 putative drug transporter genes, 
encoded by Plasmodium falciparum chloroquine resist-
ance transporter (pfcrt) and Plasmodium falciparum 
multidrug resistance protein 1 (pfmdr1), could be a 
possible cause [13], and such mutations are selected 
in infections following recent treatment with ASAQ 
[14, 15]. The resistance could spread given that amodi-
aquine is associated with sulfadoxine-pyrimethamine 
(AQ/SP) for the seasonal malaria chemoprophylaxis 
(SMC) adopted in many Sahelian countries, includ-
ing Burkina Faso [16, 17]. Decreased susceptibility of 
P. falciparum isolates to lumefantrine was reported 
in African children particularly in those who were 
recently treated with artemether–lumefantrine (AL) 
[14]. This situation is of concern as ACT are currently 
the most potent drug available to treat uncomplicated 
malaria [18].
In Burkina Faso, standard treatment for uncompli-
cated malaria changed in 2005 from chloroquine to AL 
and ASAQ as first line treatments and since then, ACT 
coverage has improved [19]. While this improved cov-
erage is welcome, it also bears the potential of resistant 
parasite selection as drug pressure, secondary to poor 
treatment practices, inadequate patient adherence to 
prescribed drug regimens, and usage of sub-standard 
forms of the drug, is a key factor in the emergence of 
resistance [20].
Given the history of resistance to the previous anti-
malarial drugs, the presence of artemisinin-resistant 
P. falciparum malaria in South-East Asia and the risk 
that resistance appearing elsewhere reach sub-Saharan 
Africa, there is a continuous need for local and global 
surveillance to collect up-to-date information that will 
detect early signs of resistance and trigger national, 
regional and global action [21]. Therefore, the regular 
surveillance of P. falciparum sensitivity against arte-
misinin-based combinations in sub-Saharan Africa is 
needed. So far, apart from the standard in  vivo drug 
efficacy recommended by the WHO for the assessment 
of anti-malarial drug [22], there are no validated molec-
ular markers of resistance to artemisinin derivatives, 
although P. falciparum chromosome 13 (‘kelch’ motif or 
K13) (pfk13) was associated with slow in vivo parasite 
clearance in south east Asia [7–9]. In such context, the 
combined ex vivo and in vivo tests present a tool to reg-
ularly assessed ACT efficacy [23–26]. The combination 
of these tests offers a comprehensive assessment of the 
efficacy of anti-malarial dugs and enables the predic-
tion of the possible emergence of drug resistance. This 
can subsequently aid the guidance of locally-adapted 
anti-malarial drug prescription policies. The purpose 
of this study was to assess the coupled ex vivo/in vivo 
efficacy of AL and ASAQ for the treatment of uncom-
plicated P. falciparum malaria in children from a semi-
urban area of Burkina Faso.
amodiaquine is associated in seasonal malaria chemoprophylaxis (SMC) mass drug administration in children under 
5 years in Burkina Faso.
Trial registration clinicaltrials, NCT00808951. Registered 05 December 2008,https://clinicaltrials.gov/ct2/show/NCT008
08951?cond=NCT00808951&rank=1
Keywords: Artemisinin-based combination therapy, In vivo/ex vivo, Efficacy, Safety, Uncomplicated malaria, 
Paediatric, Sub-Saharan Africa, Burkina Faso
Page 3 of 13Lingani et al. Malar J            (2020) 19:8 
Methods
Study design and sites
This was a phase IV, open label controlled trial, ran-
domized two-parallels arms, using a modified WHO 
2009 protocol for surveillance of anti-malarial drug effi-
cacy [22]. The study was carried out in a semi urban area 
of Bobo-Dioulasso in western Burkina Faso between 
December 2008 and December 2010, 5  years after the 
country had adopted and implemented the new first-line 
treatment protocols for uncomplicated malaria which 
is still currently in use in the country. The study area is 
characterized by a climate of Sudano-Guinean type, with 
an alternating rainy season from June to November and 
dry season from December to May. Malaria is hyperen-
demic with seasonal transmission but can be perennial 
around rivers and rice paddies with peak transmission 
during the rainy season [27]. The commonest vectors are 
Anopheles gambiae sensu stricto (s.s.), Anopheles funes-
tus and Anopheles arabiensis, and P. falciparum is the 
predominant malaria parasite [27–29].
Patients and inclusion criteria
During the study period, all male and female patients 
aged 6 months to 15 years inclusive, with fever (axillary 
temperature ≥ 37.5 °C) or history of fever in the last 24 h, 
visiting the peripheral health centres of the Dafra health 
district catchment area were screened using light micros-
copy. Children weighing 5 kg or more, with a confirmed 
P. falciparum (parasitaemia ≥ 4000/μL to 200,000/μL) 
mono-infection, haemoglobin level above 5.0  g/dl, and 
agreed to participate whenever applicable by giving their 
assent and if their parents or guardian provided writ-
ten informed consent. Patients were not included if they 
were not willing to participate or had participated to any 
drug trial within the last 30  days, or had known hyper-
sensitivity to the study drug, or were severely malnour-
ished (defined as weight for height < 70% of the median 
NCHS/WHO reference), or had severe malaria. Patients 
were excluded after randomization if slide re-evaluation 
demonstrated a parasite density or species outside the 
inclusion criteria, if the patient experienced repeated 
vomiting of study medications on day 0, anti-malarial 
drug intake outside the study protocol during the follow-
up period, or a voluntary consent withdrawal. For each 
included participant, five millilitres of venous blood were 
collected in EDTA coated tubes (Turumo, Escap, Bel-
gium) for ex vivo assessments.
Laboratory procedures for parasitaemia, haemoglobin 
and polymerase chain reaction (PCR)
Blood smear were obtained to check the presence of 
P. falciparum and to estimate the parasitaemia at day 0 
(before inclusion) and at each scheduled or unscheduled 
visit. Thick and thin blood films were prepared, dried and 
Giemsa-stained according to standard operating pro-
cedures and examined under light microscopy at 1000-
time magnification. Parasite density was calculated by 
counting the number of asexual parasites per 200 white 
blood cells (WBC) in the thick blood film, based on an 
assumed WBC of 8000/μl. One hundred high-powered 
fields (HPF) were examined (independent of presence or 
absence of asexual parasite stages). The parasite density 
per microlitre was calculated using the following formula: 
W   Parasite density/µI = (number of parasites counted × 8000)
/
(
number of leukocytes counted
)
 Blood smears were 
examined by two readers and, in the case of discord-
ant results, by a third reader. Discordant results were 
defined as a difference between the two readers in (a) 
Plasmodium species, (b) positive and negative, (c) with 
parasite > 400/μL; if the higher count divided by the lower 
count was > 2, (d) with parasite ≤ 400/μL; if the higher 
reading is > log10 higher than the lower reading. Hae-
moglobin level was measured at day 0, 14, 28, 42 and any 
unscheduled visit with a portable spectrophotometer 
(HemoCue, Ängelholm, Sweden).
From included patients, four drops of blood were col-
lected on filter paper (Whatman grade 3), labelled, 
air-dried and stored in seal plastic bags at ambient tem-
perature. Parasite DNA was subsequently extracted 
using the Qiagen spin column kit for dry blood spots. 
For patient that experience treatment failure after day 6, 
parasite collected at day 0 and at day of treatment failure 
were genotype in stepwise fashion using GLURP (gluta-
mate rich protein), MSP1 (merozoite surface protein 1) 
and MSP2 (merozoite surface protein 2) according to the 
standard WHO protocols [30]. If for any of the 3 loci, an 
allele was not share between day 0 and time of treatment 
failure, the infection was classified as new infection. If 
at least one matched allele was found at every locus, the 
outcome was classified as a recrudescence.
Ex vivo assays
Ex vivo tests were described elsewhere [31]. Briefly, isolates 
of P. falciparum (parasitaemia ≥ 4000/μL to 200,000/μL) 
were collected before treatment and at day of recurrent par-
asitaemia. Drug sensitivity tests were performed within 24 h 
of bleeding, without culture adaptation using the modified 
isotopic micro-test technique [25]. The drugs tested were 
lumefantrine (Novartis Pharma, Basel, Switzerland), dihy-
droartemisinin (Sigma Tau., Rome, Italy) and monodeseth-
ylamodiaquine (WHO/TDR, Geneva, Switzerland).
Interventions and follow up
At inclusion (day 0), patients who met the eligibility cri-
teria were randomly assigned to receive either AL (a 
fixed-dose combination of 20  mg artemether/120  mg 
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lumefantrine;  Coartem® Novartis) or ASAQ (a fixed-dose 
combination of artesunate and amodiaquine at three dif-
ferent dosages; Coarsucam™, Sanofi Aventis). Treatment 
were allocated on a computer-generated randomization 
list basis provided by an off-site investigator. Opaque 
sealed envelopes were prepared according to the rand-
omization list with unique codes corresponding to the 
allocated treatment. Treatment allocation was done only 
after all eligibility criteria were confirmed. According to 
weight-based guidelines, a study nurse supervised the 
oral administration of AL [1 (patient weight, 5–14  kg), 
2 (15–24  kg), or 3 (25–34  kg) and 4 (≥ 35  kg) tablets 
twice daily for 3  days] with fatty food or ASAQ [1 tab-
let of 25  mg artesunate/67.5  mg amodiaquine (5–9  kg), 
50 mg/135 mg (9–18 kg), or 100 mg/270 mg (18–36 kg) 
once daily for 3 days] with water.
In this study all the participants treatments were 
directly observed by a study nurse at the clinic in both 
groups. In the AL group where patients had two admin-
istration each day, patients who lived far from the clinic 
stayed for the evening dose. And those living close to 
the centre and who wished, were allowed to leave and 
return at the clinic for the evening dose. After study 
drug administration, all children were observed at the 
clinic for an hour. A full dose was repeated if vomiting 
occurred within 30  min of administration and halved if 
vomiting occurred between 30  min and 1-h. Children 
(or caregivers) were provided with paracetamol for treat-
ment of febrile symptoms. Those with a haemoglobin 
level of < 10 g/dL were treated with ferrous sulphate and 
anthelmintic.
Patients were asked to return on days 1, 2, 3, 7, 14, 21, 
28, 35, and 42, as well as any other day if they felt ill, for 
a standardized medical history and physical examination. 
Blood sampling by finger prick was carried out for thick 
blood smears and for storage on filter paper at day 7, 14, 
21, 28, 35, 42 and any unscheduled day if they feel unwell. 
Haemoglobin level was measured on day 0, day 14, day 
28, day 42 and at the time of unscheduled visits. Patients 
who did not return for follow-up were visited at home. 
Treatment failures were treated with quinine 10  mg/kg 
orally three times a day for 7  days. Patients who devel-
oped evidence of severe malaria (including those who’s 
haemoglobin dropped at a level < 5 g/dL) or danger signs 
(convulsions, lethargy, inability to drink or breast feed, 
repeated vomiting, inability to stand/sit due to weakness) 
were referred for treatment with parenteral quinine and 
supportive care at the Bobo-Dioulasso University Hospi-
tal. Patients were excluded from the per-protocol popula-
tion in case they used other anti-malarial drugs outside 
of the study, serious adverse events requiring a change 
of treatment, withdrawal of informed consent, or loss 
to follow-up. At the end of 42-day follow up, treatment 
outcomes were assessed based on the WHO 2009 pro-
tocol for surveillance of anti-malarial drug efficacy: 
adequate clinical and parasitological response (ACPR), 
early treatment failure (ETF), late parasitological failure 
(LPF), and late clinical failure (LCF) (Additional file  1). 
Total treatment failure was calculated as the sum of ETF, 
LPF and LCF [22]. Adverse events and serious adverse 
events were recorded, assessed and follow-up through-
out the trial and up to completion of each event. Adverse 
event was defined as any untoward medical occurrence 
in a patient administered a pharmaceutical product and 
which does not necessarily have a causal relationship with 
the treatment. A serious adverse event was any adverse 
event that resulted in patient death, was life-threatening, 
required inpatient hospitalization or a prolongation of 
an existing hospitalization, required an intervention to 
prevent permanent impairment or has caused congenital 
anomaly.
Ethical considerations
Artemether–lumefantrine and artesunate plus amodi-
aquine are the first line anti-malarial treatments in Bur-
kina Faso, so this was considered as a phase IV study 
with low-risk for participants. The study protocol was 
reviewed and approved by the institutional ethics com-
mittee of Centre Muraz in Burkina Faso (Deliberation 
18-2009/CE-CM). Informed consent was obtained from 
individual study participants in the presence of an inde-
pendent witness whenever the participant was illiterate. 
Children aged 12  years and over were asked to provide 
their assent if they were able to do so. Written informed 
consent was obtained from the guardians for all chil-
dren before entering the study. The study was conducted 
according to the WHO Good Clinical Practices guide-
lines and according to Burkina Faso national regulations.
Statistical analysis
AL and ASAQ were adopted by Burkina Faso National 
Malaria Control Programme in 2005 on a non-inferior-
ity basis with both treatments used as alternative first-
line treatment for uncomplicated malaria. In the current 
phase IV study, it was hypothesized that the efficacy of 
each study treatments is likely to be at least 90%. There-
fore, 220 children per arm would be able to show at the 
5% significance level with 95% power, and a maximum 
loss to follow up of 10%, that the difference in efficacy 
between treatments is not more than 10%.
Data were double entered and verified with Microsoft 
Access 2007 and analysed with Stata 15 software (Stata-
Corp. TX, USA). Efficacy and safety data were evaluated 
using a modified intention-to-treat analysis that included 
all enrolled patients and also using a per-protocol analy-
sis included all participants who did not experience any 
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major protocol violation. Risks of new infections and 
recrudescence during the 42-day follow-up were esti-
mated using the Kaplan–Meir product-limit formula and 
comparisons of cumulative risk with the non-paramet-
ric log-rank test. Data were censored for patients who 
did not complete the follow-up and for infections due 
to another Plasmodium species. Other categorical vari-
ables were compared with Chi square or Fisher exact test, 
and continuous variables were compared using the inde-
pendent-samples t-test. The ex  vivo data management 
and statistical methods are described elsewhere [31]. A p 
value of < 0.05 was considered statistically significant.
Results
Trial subjects
Figure 1 summarizes the trial profile. Out of 950 children 
aged between 6 months and 15 years screened for a suspi-
cion of malaria, 643 (67.7%) were positive for falciparum 
malaria. In total, 440 children fulfilling the eligibility cri-
teria were recruited and randomized to receive either AL 
Fig. 1 Trial profile: 42-day follow-up of study participants by treatment arm at the Dafra health district medical centre, Burkina Faso 2008-10. AL 
artemether–lumefantrine, ASAQ artesunate–amodiaquine
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or ASAQ at a ratio of 1:1. At the end of the 42 days follow 
up period, 213 in the AL arm and 207 in the ASAQ arm 
completed the study. One patient with a negative blood 
smear on third and 7th day of follow-up died before the 
day 14 follow up visit for a suspicion of meningitis. Eight 
participants were lost to follow-up, and other seven par-
ticipants stopped their participation as their caregivers 
moved outside the study catchment area. Four partici-
pants were excluded from the per-protocol population: 
one participant for persistent vomiting, two participants 
for taking anti-malarial drugs outside the study protocol, 
and the other one for severe malaria with haemoglobinu-
ria. Baseline characteristics including mean age, height, 
and mean geometric parasite density were similar for 
children assigned to the 2 study arms excepted for the 
gender ratio with however no significant impact on out-
come analysis (Table 1).
In vivo efficacy of trial regimens
The large majority of treatment failures were late parasi-
tological failures, with fewer children having a late clini-
cal failure (Table 2). In per protocol population (N = 420 
participants 213 in the AL arm and 207 in the ASAQ 
arm), the PCR-unadjusted cure rate at day 42 was sig-
nificantly higher in the ASAQ arm (71.0%) than in the 
AL arm (49.8%) [risk difference = − 22.0; 95% CI − 31.1; 
− 12.9 (p < 0.001)]. Trend remained similar, after adjust-
ment by PCR, between ASAQ (98.1%) and AL (91.1%) 
[risk difference = − 7.0; 95% CI − 11.0; − 2.7 (p < 0.001)].
In intent-to-treat population (N = 440 participants 220 
in the AL arm and 220 in the ASAQ arm), the PCR-unad-
justed cure rate at day 42 was still significantly higher in 
the ASAQ arm (66.8%) than in the AL arm (48.2%) [risk 
difference = − 18.6; 95% CI − 27.4; − 9.4 (p < 0.001)]. 
Table 1 Baseline characteristics of  the  study participants 
by  treatment arm at  the  Dafra health district medical 
centre, Burkina Faso, 2008–2010
AL artemether–lumefantrine, ASAQ artesunate plus amodiaquine, GMPD 
geometric mean of parasite density
Intention to treat 
population 
mean ± standard 
deviation
ASAQ N = 220 AL N = 220 Total N = 440
Gender m/f, % 45.4/54.6 55.6/44.6 50.5/49.6
Age, year 6.4 ± 3.2 6.4 ± 3.1 6.5 ± 3.1
Height, cm 114.3 ± 19.4 114 ± 19.5 114.15 ± 19.4
Weight, kg 19.1 ± 7.5 18.9 ± 8.0 19.01 ± 7.7
GMPD, parasitaemia/µl 44567 47074 45803
Table 2 PCR-adjusted and  unadjusted cure rates of  the  study participants at  day-42 at  Dafra health district medical 
centre, Burkina Faso, 2008–2010
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, CI 95% confident interval, n number, % percentage
Outcome: day 42 AL ASAQ Difference (CI 95%) p-value
Variables
PCR corrected efficacy outcome—no. (%)
Per protocol population (N = 420) n (%) 213 207 – –
 Adequate clinical and parasitological response 194 (91.1) 203 (98.1) − 7 (− 11.0 to − 2.7) < 0.0006
 Early treatment failure 0 (0.0) 0 (0) – –
 Late clinical failure 0 (0.0) 0 (0) – –
 Late parasitological failure 19 (8.9) 4 (1.9) – –
 Total number of failure 19 (8.9) 4 (1.9) – –
Not corrected for reinfection n (%)
 Adequate clinical and parasitological response 106 (49.8) 147 (71.0) − 22 (− 31.1 to − 12.9) < 0.0001
 Early treatment failure 0 (0) 0 (0) – –
 Late clinical failure 32 (15.0) 22 (10.6) – –
 Late parasitological failure 75 (35.2) 38 (18.4) – –
 Total number of failure 107 (50.2) 60 (28.9) – –
Intent-to-treat population (N = 440) 220 220 – –
 PCR-adjusted
 Total number of patients n 194 203
 Adequate clinical and parasitological response % (95% CI) 88.2 (83.2–91.8 92.3 (87.9–95.2) − 4.1 (− 9.8 to − 1.5) 0.148
 PCR-unadjusted
 Total number of patients n 106 147 – –
 Adequate clinical and parasitological response % (95% CI) 48.2 (41.6–54.8) 66.8 (60.3–72.8) − 18.6 (− 27.4 to 9.4) < 0.001
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However, difference of PCR adjusted cure rate was not 
statistically significant between ASAQ (92.3%) and AL 
(88.2%) [risk difference = − 4.1; 95% CI − 9.8; − 1.5 
(p = 0.148)].
New infection started to appear after day 14, first in 
the AL arm and then in ASAQ arm and (the difference) 
was statistically significant at day 42 (p < 0.001) (Fig. 2a). 
However, recrudescence started to appear after day 
21, first in the AL arm and then in the ASAQ arm and 
this (difference) was statistically significant at day 42 
(p < 0.001) (Fig.  2b). The rate of treatment failure (new 
infection and recrudescent was significantly lower in the 
ASAQ arm than in the AL arm (p < 0.001) (Fig. 2c). After 
the completion of treatment (day 3), almost all the par-
ticipants (418/420, 99.5%) had negative blood smear (two 
patients in the AL group had positive blood smears).
At day 0, approximately 6.8% (15/220) in AL arm and 
4.5% (10/220) in ASAQ arm had positive blood smear for 
gametocyte (p > 0.05). Gametocytes clearance was slower 
in ASAQ arm (8% positive) than in AL arm (2.8%) at day 
7 (p = 0.03), and total clearance was observed at day 42. 
The fever clearance was rapid in both treatment arms, 
and no patient was febrile on day 3 following the treat-
ment initiation. The average increase in haemoglobin 
level at day 42 was significantly higher compared to base-
line in the two arms and there was no statistically sig-
nificant difference between both arms (0.9 g/dL in ASAQ 
versus 0.7 g/dL in the AL arm; P > 0.05).
Both treatments were well-tolerated with no signifi-
cant difference in the incidence of adverse events (AE) 
(Table  3). However, one fatal case of suspected cer-
ebrospinal meningitis in AL arm and one case of severe 
malaria with haemoglobinuria in ASAQ arm were 
recorded as serious adverse events.
Ex vivo efficacy of study drug active metabolites
Table 4 summarizes the mean 50% inhibitory concentra-
tion (IC50) of monodesethylamodiaquine (MDA), the 
active metabolite of amodiaquine, dihydroartemisinin 
(DHA), the active metabolite of artemisinin derivatives 
and lumefantrine (Lum) at day 0 as baseline values, and 
the proportion of resistant isolates, i.e. IC50 above the 
cut-off of resistance. Cut-off value was set at 60 nM for 
MDA. However, there was no cut-off values for DHA and 
lumefantrine and, therefore, the resistance rates could 
not be determined for these drugs. The overall resistance 
rate to MDA was 6.4%.
Coupled in vivo/ex vivo efficacy AL and ASAQ in children
From the 24 isolates (6.4%) resistant to MDA at inclu-
sion, the treatment outcome resulted in one recrudescent 
Fig. 2 Kaplan Meier curves showing the treatment failure cumulative 
proportion for each treatment arm by day 42 in the per protocol 
population (N = 420): a recrudescent infections, b new infection, c 
recurrent infections (Recrudescent plus new infection)
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case, 11 ACPR cases, and 12 new infection cases. Figure 3 
compares the mean IC50 values at inclusion between 
participants with adequate clinical and parasitological 
response (ACPR) and patients with treatment failure. The 
IC50 values at inclusion could not adequately predict the 
treatment outcome during the follow-up period as mean 
values were similar between the ACPR, the recrudes-
cence and the new infection group.
In the ASAQ arm, mean IC50 values were not signifi-
cantly different on day of treatment failure compare to 
baseline (p > 0.05) for MDA and DHA (Table  5). Simi-
larly, in the AL arm, the mean IC50 values were not sig-
nificantly different between day of treatment failure and 
baseline for DHA, although for lumefantrine the increase 
was particularly high (p = 0.05) (Table 5).
Discussion
In this study, the efficacy and safety of the two arte-
misinin-based combinations used as first-line treatment 
for uncomplicated malaria in Burkina Faso were inves-
tigated. Noteworthy their importance for malaria man-
agement, amodiaquine the partner drug in the ASAQ 
combination is used in the seasonal malaria chemopre-
vention strategy although there is a WHO recommenda-
tion discouraging such use of first-line drug component 
in mass drug administration within the same zones [32]. 
Given that no efficacy study assessing the two combina-
tions was conducted during the last 10 years in the coun-
try; these results, even if dating back to 2010, can still 
bring useful information to policymakers as it combines 
both ex vivo and in vivo data.
Both AL and ASAQ were highly effective in clear-
ing malaria infections with PCR adjusted cure rates 
over 90%, a threshold required by the WHO for an anti-
malarial to be considered effective [33]. However, ASAQ 
presented a higher cure rate than AL although the differ-
ence was within the pre-specified 10% points margin of 
equivalence. Therefore, based on these data, the choice 
of the two artemisinin-based combinations as first-line 
treatment for uncomplicated P. falciparum malaria was 
appropriate in Burkina Faso. Efficacy of both treatment 
was evaluated in other sub-Saharan African countries 
and similar good efficacy were reported in west Africa 
[34–38], and in eastern Africa [11, 39]. In the current 
study, both treatments were equally efficacious with 
however, most treatment failure observed in AL arm 
(8.9%). The possible declining in AL efficacy should alert 
the national malaria program to undertake more fre-
quent surveillance. In particular, the data presented here 
refer to the years 2010, so such a phase IV study would 
be now timely in Burkina Faso. Noteworthy, a previous 
study conducted in the same area, when the new proto-
col was not yet scaled-up, reported better cure rates with 
AL (95.9%) and ASAQ (96.1%) [40]. Within 5  year, an 
important decline was reported in the efficacy rate of AL 
from 95.9% to 91%. Similar trend was observed in Libe-
ria, a west African country, where high efficacy rates were 
reported for ASAQ (99.1%) and AL (94.2%) before the 
policy change [41]. By contrast, in Eastern Africa AL was 
more efficacious than ASAQ even though the differences 
were not statistically significant. Indeed, Mårtensson 
et al. in their study in Tanzania reported higher efficacy 
of AL (94%) than AS + AQ (91%) [42]. In the Democratic 
Republic of Congo, Epsié et  al. reported higher efficacy 
of AL (99.1%) than AS + AQ (98.3%) [43]. This contrast-
ing results between Western Africa and Eastern Africa 
could be explained by the better efficacy of amodiaquine 
the partner drug in the ASAQ combination in West-
ern Africa than Eastern Africa, and could be the reason 
behind the better efficacy of artesunate-amodiaquine 
in this study [44, 45]. Both regions have also high pfcrt 
76T prevalence, with however a rapid decline in Eastern 
Africa than in Western Africa and this varying preva-
lence of pfcrt 76 T could influence the efficacy of the 
combination [46].
Table 3 Safety and tolerability outcome
AE adverse event, SAE serious adverse event, AL artemether lumefantrine, ASAQ 
artesunate–amodiaquine
Adverse events AS + AQ n (%) AL n (%) p-value
Overall 88 (40.0) 87 (39.5) 1.00
Specific AEs
 Abdominal pain 18 (8.1) 17 (7.7) 1.00
 Digestive (nausea, vomit-
ing, anorexia, diarrhea)
22 (10.0) 22 (10.0) 0.86
 Cough and rhinitis 23 (10.5) 28 (12.7) 0.55
 Bronchitis 12 (5.4) 13 (5.9) 1.00
 Fever 40 (18.2) 47 (21.4) 0.47
 Headache 16 (7.3) 21 (9.5) 0.49
 Other events 17 (7.7) 12 (5.5) 0.44
 SAE of any cause 1 (0.5) 1 (0.5) 1.00
Table 4 Mean values of  50% inhibitory concentration 
of anti-malarial drug at day 0
a No cut-off value for resistance defines
Anti-malarial IC50 Geometric 








19.30 (18.04–20.65) 0.81 595.93 24 (6.37)
Dihydroartemisinina 0.83 (0.76–0.89) 0.15 38.73 –
Lumefantrinea 25.12 (22.40–28.16) 0.77 166.1 –
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Fig. 3 Mean geometric IC50 values at day 0 and treatment outcome in study participants at the Dafra health district medical centre, Burkina Faso 
2008–2010: a artemether–lumefantrine arm, b artesunate amodiaquine arm. D0 day of inclusion before treatment administration, NI new infection, 
R recrudescent, ACPR adequate clinical and parasitological response, DHA dihydroartemisinin, Lum lumefantrine, MDA monodesethylamodiaquine, 
IC50 50% inhibitory concentration
Table 5 Mean geometric IC50 values for  each component of  AL and  ASAQ at  D0 (before treatment) versus  day 
of treatment failure among treatment participants
nM nanomolar, DoR day of recurrent parasitaemia, ASAQ amodiaqine–artesunate, AL artemether lumefantrine, MDA monodesethylamodiaquine, DHA 
dihydroartermisinin, LUM lumefantrine
Treatment n n P value
IC50 at D0 in nM (IC 95%) IC50 at DoR in nM (IC 95%)
ASAQ
 MDA 188 33 –
19.80 (17.83–21.99) 24.94 (20.68–30.08) 0.94
 DHA 190 34 –
0.85 (0.76–0.95) 0.66 (0.47–0.93) 0.96
AL
 DHA 191 54 –
0.8 (0.72–0.90) 0.67 (0.54–0.83) 0.43
 LUM 192 53 –
24.13 (20.45–28.46) 37.07 (28.37–48.44) 0.05
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In the same period as in this study, ASAQ (89.7%) 
and AL (89.8%) presented lower efficacy rate in Nanoro, 
northern part of the country with a different malaria 
transmission pattern [47]. Although in the present study 
all treatments administrations were directly observed, 
this alone cannot explain this difference as the cure rate 
in this study remain higher in the intent-to-treat popula-
tion. The difference in the malaria transmission profiles 
(Sudano-Sahelian type of climate with shorter transmis-
sion season than in the western part) between the two 
regions could be behind the observed difference as geo-
graphic variations in ACT efficacy were already reported 
elsewhere [48].
From a clinical point of view, any recurrent parasitae-
mia should be treated with an efficacious anti-malarial 
regardless whether it is recrudescence or new malaria 
infection, so the most practical means of assessing 
these drugs may be to evaluate their impact on recur-
rent malaria. By this measure, recurrent parasitaemia 
rates were high in both arms with however a remarkably 
higher rate in the AL arm (50.2%). Most studies in sub-
Saharan Africa reported similar results with up to 40% 
of recurrent parasitaemia [35, 40, 42, 49]. The duration 
of post treatment prophylaxis is however an important 
criterium in the choice of anti-malarial drugs, especially 
in areas with a high risk of re-infection. These post treat-
ment prophylactic effects are mainly related to the elimi-
nation half-life of the partner drug. Lumefantrine has 
the shortest elimination half-life (3–5  days) [50], then 
followed by monodesethylamodiaquine (10–18  days) 
[51], and could be the reason behind the better efficacy 
of artesunate plus amodiaquine. However, a prolonged 
elimination and protection time may drive the develop-
ment of resistance in a setting of high malaria transmis-
sion due to frequent and longer exposition of parasite to 
decreased drug concentration level in patient blood [52].
The main goal of the coupled in  vivo/ex vivo analysis 
was to predict the treatment outcome based on the values 
of the IC50 at baseline. However, this was not possible 
within this study as only one (1/24) patient resistant to 
monodesethylamodiquine at day 0 was a true treatment 
failure. This raises the issue of defining appropriate IC50 
thresholds to adequately predict the in vivo outcomes.
The mean IC50 values was higher at recurrent parasi-
taemia than at day 0 for both artemether lumefantrine 
and artesunate amodiaquine. If that increase was not sta-
tistically significant for monodesethylamodiaquine, due 
possibly to the limited number of recrudescence in the 
artesunate–amodiaquine arm, it was however high for 
lumefantrine. A prior study in east Africa reported a sig-
nificant directional selection for Pfmdr1 184F in recurrent 
malaria infections after treatment with AL in Uganda [48]. 
This evidence highlight the dynamic evolutionary status 
of the susceptibility of P. falciparum to lumefantrine, par-
ticularly in patients recently treated with AL. This advo-
cate for a regular surveillance of lumefantrine in the AL 
combination. Although both AL and ASAQ performed 
well with few recrudescence, changes in the relative per-
formance of the 2 partner drugs should draw the attention 
of policymakers, especially considering the very high inci-
dence of malaria in Burkina Faso. Remarkably, nearly half 
of children treated with AL experienced recurrent malaria 
within 42 days. This risk was 40% lower in children treated 
with ASAQ, suggesting important benefits of this regi-
men. However, these data and prior results suggest that 
widespread use of ASAQ may rapidly select parasites with 
reduced susceptibility [14–16]. This is quite alarming as 
amodiaquine is used for the seasonal malaria chemopro-
phylaxis in sub-Sahel countries [53, 54].
Both drugs presented a good safety profile with low 
incidence of adverse events. Fever and headache were 
common in both treatment arm and were likely to be 
symptoms of the malaria infection. Cough was also fre-
quent in both arm and may be related to additional bac-
terial infections as clinical bronchitis was also a common 
finding. Abdominal pain, anorexia and diarrhoea were 
relatively common in both arms and were related to the 
malaria infection. Two cases of serious adverse events 
were reported in this study.
The first case was about a 5  years of age female child, 
weighing 18 kilograms of body mass, high fever (39.5 ℃) 
with a baseline parasitaemia of 127,788/µl, an inclusion 
haemoglobin level of 9.8  g/dL and who received his first 
dose of ASAQ, presented 12 h later a febrile status asso-
ciated to a diuresis of 250 ml of brownish urines. The 
diagnosis of haemoglobinuria was suspected by study phy-
sician and participant was discontinued from the study 
treatment and referred to Bobo-Dioulasso university hos-
pital where the diagnosis was confirmed. Participant was 
managed at the hospital with intravenous artesunate and 
recovered before day 7. This occurrence was classified as 
related to the study drug by the study physician.
The second case was a 5  years old male child, weigh-
ing 12 kilograms, with high inclusion fever (40.5  ℃), 
a haemoglobin level of 7.9  g/dL, an inclusion parasite 
level of 104, 301 asexual parasites/µl, treated with AL 
and well recovered with negative blood smear on day of 
study completion and confirmed on day-7 follow-up. The 
patient missed his day-14 scheduled visit and an inves-
tigator visited his caregivers home and was informed 
that patient presented a febrile neurological syndrome 
on day-12 after inclusion, managed with herbal therapy 
without improvement and was referred to another health 
centre for a febrile loss of consciousness. The diagnos-
tic of bacterial meningitis was suspected and treated 
using intravenous ceftriaxone, blood transfusion and 
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supportive care. The meningitis diagnostic could not be 
confirmed due unsuccessful lumbar puncture and subse-
quent child death. The serious adverse event was classi-
fied as not related to the study treatment.
Conclusion
Both artemether–lumefantrine and artesunate amodi-
aquine are appropriate as first-line treatment of uncom-
plicated malaria in Burkina Faso, based on the findings 
of this phase IV study since both presented PCR adjusted 
cure rates above 90%. However, the post-treatment 
prophylaxis was unsatisfactory for both treatment par-
ticularly for artemether–lumefantrine and advocate regu-
lar surveillance of the efficacy of the two combinations. 
Given that these data are a bit old, it seems timely to con-
duct new surveillance study in the country to produce 
updated information. In addition, any alternative drug 
should be investigated.
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